Andrea Katharina Lindner
Papers
1
Total Citations
8
H-Index
1
About
Andrea Katharina Lindner is a translational cancer researcher whose work centers on identifying genomic biomarkers to improve treatment outcomes in muscle-invasive bladder cancer (MIBC). Her major contribution lies in uncovering the molecular underpinnings of chemotherapy resistance. In her landmark 2019 study, she demonstrated that amplification of chromosomal region 7p12 is significantly associated with pathologic nonresponse to neoadjuvant chemotherapy (NAC). This finding is critical, as only 30–40% of MIBC patients achieve pathologic downstaging—a key predictor of survival—leaving a majority without effective treatment options. By pinpointing this genomic alteration, Lindner provides a potential predictive biomarker to guide therapy selection, sparing non-responders from ineffective toxicity. Her work, cited 8 times, addresses a pressing clinical need and lays the groundwork for personalized approaches in bladder cancer. Through her research, Lindner is helping to bridge the gap between genomic discovery and clinical decision-making, offering new hope for more precise, effective cancer care.
Research Focus
Key Achievements
Top Papers
- 1